Stock Scorer

Praxis Precision Medicines, Inc. (PRAX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 3M 6M 9M Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 683K Q2 '23: 781K Q3 '23: 468K Q4 '23: 515K Q1 '24: 431K Q2 '24: 357K Q3 '24: 302K Q4 '24: 7.5M Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q2 '22 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q3 '21: -44.8M Q4 '21: -58.7M Q1 '22: -68.8M Q2 '22: -60.4M Q3 '22: -44.3M Q4 '22: -41.5M Q1 '23: -38.1M Q2 '23: -35M Q3 '23: -25.5M Q4 '23: -27.8M Q1 '24: -41.9M Q2 '24: -37.5M Q3 '24: -56.8M Q4 '24: -64M Q1 '25: -74.7M Q2 '25: -76.1M Q3 '25: -78.4M Q4 '25: -97M Q1 '26: -105.9M Q2 '26: -96.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -44.7M Q4 '21: -58.6M Q1 '22: -68.7M Q2 '22: -60.2M Q3 '22: -43.9M Q4 '22: -41.2M Q1 '23: -37.5M Q2 '23: -34.3M Q3 '23: -24.6M Q4 '23: -26.9M Q1 '24: -39.6M Q2 '24: -32.7M Q3 '24: -51.9M Q4 '24: -58.7M Q1 '25: -69.3M Q2 '25: -71.1M Q3 '25: -73.9M Q4 '25: -88.9M Q1 '26: -92.6M Q2 '26: -83.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -24M Q4 '21: -44.9M Q1 '22: -54.1M Q2 '22: -57.2M Q3 '22: -44.9M Q4 '22: -28.8M Q1 '23: -32.8M Q2 '23: -31.2M Q3 '23: -23.2M Q4 '23: -23.9M Q1 '24: -20.9M Q2 '24: -27.3M Q3 '24: -27.5M Q4 '24: -56.1M Q1 '25: -53M Q2 '25: -54.7M Q3 '25: -65.1M Q4 '25: -76.3M Q1 '26: -86.2M Q2 '26: -77.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '21: -25.7M Q2 '21: -30.1M Q3 '21: -24.4M Q4 '21: -45.4M Q1 '22: -54.4M Q2 '22: -57.3M Q3 '22: -45M Q4 '22: -28.8M Q1 '23: -32.8M Q2 '23: -31.2M Q3 '23: -23.2M Q4 '23: -23.9M Q3 '24: -27.5M Q4 '24: -56.1M Q1 '25: -53M Q2 '25: -54.7M Q3 '25: -65.1M Q4 '25: -76.3M Q1 '26: -86.2M Q2 '26: -77.8M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 1.6M Q3 '20: 1.7M Q1 '21: 38.5M Q2 '21: 41.6M Q3 '21: 44.7M Q1 '22: 45.5M Q2 '22: 45.5M Q3 '22: 45.8M Q1 '23: 3.5M Q2 '23: 4.6M Q3 '23: 9M Q1 '24: 13.9M Q2 '24: 18.8M Q3 '24: 18.9M Q1 '25: 21.1M Q2 '25: 21.5M Q3 '25: 22M Q1 '26: 28.9M Q2 '26: 29.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-90.00 -60.00 -30.00 0.00 30.00 60.00 90.00 Q3 '21: 16.01 Q4 '21: -3.92 Q1 '22: -4.72 Q2 '22: -5.16 Q3 '22: -5.12 Q4 '22: -69.65 Q1 '23: -78.72 Q2 '23: -84.78 Q3 '23: -86.54 Q4 '23: -22.64 Q1 '24: -14.90 Q2 '24: -9.26 Q3 '24: -9.29 Q4 '24: -10.33 Q1 '25: -10.78 Q2 '25: -12.35 Q3 '25: -12.96 Q4 '25: -13.47 Q1 '26: -13.38 Q2 '26: -12.94 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for PRAX: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.